Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new chemical drugs: Tranexamic Acid and Sodium Chloride Injection, and Levocarnitine Oral Solution. These approvals mark significant advancements in the company’s product offerings, enhancing its position in the pharmaceutical market by addressing bleeding disorders and carnitine deficiency.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is engaged in creating medical solutions for various health conditions, with a market focus on drug production and registration in China.
Average Trading Volume: 11,720,126
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.79B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.